HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| NGM-313 | NGM-313; MK-3655 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatitis; Obesity | Details |
| Fazpilodemab | RG-7992; BFKB-8488A; RO-7040551 | Phase 1 Clinical | Genentech Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Insulin Resistance | Details |
| B-1344 | B-1344 | Phase 1 Clinical | Tasly Biomedical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2 | Details |